{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:10:08Z","timestamp":1745467808941,"version":"3.40.4"},"reference-count":12,"publisher":"S. Karger AG","issue":"3-4","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2004]]},"abstract":"<i>Objective:<\/i> This study investigated the maximum-tolerated dose of hyperfractionated radiation therapy with protracted 5-fluorouracil (5-FU) infusion in patients with locally advanced, unresectable pancreatic cancer. <i>Methods:<\/i> Five cohorts of patients were scheduled to receive escalating doses of hyperfractionated radiation therapy (range, 45.6\u201364.8 Gy). All patients received two fractions of 1.2 Gy each (separated by 6 h) per day for 5 days a week, and received protracted 5-FU infusion (200 mg\/m<sup>2<\/sup>\/day) during the radiation course. The maximum-tolerated dose was defined as one dose level below the dose at which more than one third of 3\u20136 patients experienced dose-limiting toxicity. <i>Results:<\/i> Twenty-nine patients were enrolled in this study. The most common toxicities were nausea\/vomiting and anorexia. Although 1 patient developed bleeding from a gastric ulcer 3 months after the completion of chemoradiotherapy, the maximum-tolerated dose was not reached even at the highest dose level (level 5, 64.8 Gy). The median survival time was 12.2 months and the 1-year survival rate was 55.0%. <i>Conclusion:<\/i> The toxicity associated with our regimen was tolerable up to dose level 5 (64.8 Gy). We are currently conducting a phase II study of this hyperfractionated radiation therapy with protracted 5-FU infusion at a dose of 64.8 Gy.<\/jats:p>","DOI":"10.1159\/000081320","type":"journal-article","created":{"date-parts":[[2004,12,3]],"date-time":"2004-12-03T12:13:58Z","timestamp":1102076038000},"page":"215-221","source":"Crossref","is-referenced-by-count":3,"title":["Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer"],"prefix":"10.1159","volume":"67","author":[{"given":"Hideki","family":"Ueno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koich","family":"Tokuuye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,11,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819811015%2948%3A8%3C1705%3A%3AAID-CNCR2820480803%3E3.0.CO%3B2-4"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F80.10.751"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007%2Fs101470050065"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016%2F0167-8140%2892%2990242-M"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819900401%2965%3A7%3C1478%3A%3AAID-CNCR2820650705%3E3.0.CO%3B2-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2F0167-8140%2896%2901798-7"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819880315%2961%3A6%3C1110%3A%3AAID-CNCR2820610610%3E3.0.CO%3B2-6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2FS0360-3016%2897%2900295-2"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2820001201%2989%3A11%3C2222%3A%3AAID-CNCR10%3E3.0.CO%3B2-V"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2307%2F3576354"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS0360-3016%2802%2903791-4"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002%2F%28SICI%291097-0142%2819970415%2979%3A8%3C1516%3A%3AAID-CNCR11%3E3.0.CO%3B2-0"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/81320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:43:32Z","timestamp":1745466212000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000081320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":12,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2004,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000081320","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2004]]}}}